{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:46:27Z","timestamp":1789173987362,"version":"build-2803163510"},"reference-count":201,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The hepatitis B virus (HBV) continues to cause substantial health and economic burdens, and its target of elimination may not be reached in 2030 without further efforts in diagnostics, non-pharmaceutical prevention measures, vaccination, and treatment. Current therapeutic options in chronic HBV, based on interferons and\/or nucleos(t)ide analogs, suppress the virus replication but do not eliminate the pathogen and suffer from several constraints. This paper reviews the progress on biotechnological approaches in functional and definitive HBV treatments, including gene-editing tools, i.e., zinc-finger proteins, transcription activator-like effector nucleases, and CRISPR\/Cas9, as well as therapeutics based on RNA interference. The advantages and challenges of these approaches are also discussed. Although the safety and efficacy of gene-editing tools in HBV therapies are yet to be demonstrated, they show promise for the revitalization of a much-needed advance in the field and offer viral eradication. Particular hopes are related to CRISPR\/Cas9; however, therapeutics employing this system are yet to enter the clinical testing phases. In contrast, a number of candidates based on RNA interference, intending to confer a functional cure, have already been introduced to human studies. However, larger and longer trials are required to assess their efficacy and safety. Considering that prevention is always superior to treatment, it is essential to pursue global efforts in HBV vaccination.<\/jats:p>","DOI":"10.3390\/v15122395","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T05:47:30Z","timestamp":1702014450000},"page":"2395","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Gene-Editing and RNA Interference in Treating Hepatitis B: A Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-329X","authenticated-orcid":false,"given":"Nadiia","family":"Kasianchuk","sequence":"first","affiliation":[{"name":"Faculty of Biology, Adam Mickiewicz University in Pozna\u0144, 61-614 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-9893","authenticated-orcid":false,"given":"Krystyna","family":"Dobrowolska","sequence":"additional","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1320-5350","authenticated-orcid":false,"given":"Sofiia","family":"Harkava","sequence":"additional","affiliation":[{"name":"Junior Academy of Sciences of Ukraine, Regional Branch in Dnipro, 49000 Dnipro, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Bretcan","sequence":"additional","affiliation":[{"name":"National College \u201cIen\u0103chi\u021b\u0103 V\u0103c\u0103rescu\u201d, 130016 T\u00e2rgovi\u0219te, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1084","authenticated-orcid":false,"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Allergology, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1635","authenticated-orcid":false,"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bia\u0142ystok, 15-540 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4713-0801","authenticated-orcid":false,"given":"Piotr","family":"Rzymski","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"ref_1","first-page":"367","article-title":"Review of Current and Potential Treatments for Chronic Hepatitis B Virus Infection","volume":"17","author":"Tsai","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_2","first-page":"100034","article-title":"Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery","volume":"1","author":"Zhao","year":"2020","journal-title":"Innovation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global Prevalence, Cascade of Care, and Prophylaxis Coverage of Hepatitis B in 2022: A Modelling Study","volume":"8","author":"Gamkrelidze","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","unstructured":"WHO (2023, May 14). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B Virus Infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","unstructured":"Long, S.S. (2008). Principles and Practice of Pediatric Infectious Disease, Elsevier."},{"key":"ref_8","first-page":"123","article-title":"Extrahepatic Manifestations of Acute Hepatitis B Virus Infection","volume":"9","author":"Kappus","year":"2013","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jinf.2023.06.006","article-title":"Could Chronic HBV Infection Explain Beethoven\u2019s Hearing Loss? Implications for Patients Currently Living with Hepatitis B","volume":"87","author":"Rzymski","year":"2023","journal-title":"J. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/23744235.2020.1766104","article-title":"Mortality from Liver Diseases Attributable to Hepatitis B and C in the EU\/EEA\u2014Descriptive Analysis and Estimation of 2015 Baseline","volume":"52","author":"Quinten","year":"2020","journal-title":"Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"686962","DOI":"10.3389\/fonc.2021.686962","article-title":"Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_12","unstructured":"(2023, September 05). Total Burden Related to Hepatitis B\u2014Cause. Available online: https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/total-burden-related-hepatitis-b-cause."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2147\/CLEP.S389853","article-title":"Global Patterns and Trends in Total Burden of Hepatitis B from 1990 to 2019 and Predictions to 2030","volume":"14","author":"Zhang","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Trickey, A., Bivegete, S., Duffell, E., McNaughton, A.L., Nerlander, L., Walker, J.G., Fraser, H., Hickman, M., Vickerman, P., and Brooks-Pollock, E. (2023). Estimating Hepatitis B Virus Prevalence among Key Population Groups for European Union and European Economic Area Countries and the United Kingdom: A Modelling Study. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08433-3"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2016.08.013","article-title":"Time Trends of Chronic HBV Infection over Prior Decades\u2014A Global Analysis","volume":"66","author":"Ott","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Velkov, S., Ott, J., Protzer, U., and Michler, T. (2018). The Global Hepatitis B Virus Genotype Distribution Approximated from Available Genotyping Data. Genes, 9.","DOI":"10.3390\/genes9100495"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100574","DOI":"10.1016\/j.aohep.2021.100574","article-title":"Hepatitis B Virus Genotypes and Subgenotypes and the Natural History and Epidemiology of Hepatitis B","volume":"27","author":"Reuter","year":"2022","journal-title":"Ann. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2015.51372","article-title":"Original Article Distribution of HBV Genotypes in Poland","volume":"1","author":"Mazur","year":"2015","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5114\/ceh.2023.131225","article-title":"Trends of Infections and Mortality Due to Hepatitis B Virus (2005\u20132022) and the Potential Impact of the COVID-19 Pandemic: A Population-Based Study in Poland","volume":"9","author":"Genowska","year":"2023","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B Virus Genotypes: Global Distribution and Clinical Importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0016-5085(83)90024-0","article-title":"Delta Hepatitis in Inapparent Carriers of Hepatitis B Surface Antigen","volume":"85","author":"Farci","year":"1983","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The Hepatitis Delta Virus: Replication and Pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sagnelli, C., Sagnelli, E., Russo, A., Pisaturo, M., Occhiello, L., and Coppola, N. (2021). HBV\/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life, 11.","DOI":"10.3390\/life11020169"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(20)32657-X","article-title":"Estimating the Health Impact of Vaccination against Ten Pathogens in 98 Low-Income and Middle-Income Countries from 2000 to 2030: A Modelling Study","volume":"397","author":"Li","year":"2021","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2471\/BLT.16.178475","article-title":"Estimated Economic Impact of Vaccinations in 73 Low- and Middle-Income Countries, 2001\u20132020","volume":"95","author":"Ozawa","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Flores, J.E., Thompson, A.J., Ryan, M., and Howell, J. (2022). The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines, 10.","DOI":"10.3390\/vaccines10050793"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for Global Elimination of Hepatitis B: A Modelling Study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lancet (2022). The Lancet Viral Hepatitis Elimination: A Challenge, but within Reach. Lancet, 400, 251.","DOI":"10.1016\/S0140-6736(22)01377-0"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.gendis.2019.12.014","article-title":"Obstacles and Opportunities in the Prevention and Treatment of HBV-Related Hepatocellular Carcinoma","volume":"7","author":"Liao","year":"2020","journal-title":"Genes Dis."},{"key":"ref_31","unstructured":"EMA (2023, October 26). Hepcludex. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_33","unstructured":"Gavidia, M. (2023, October 26). FDA Rejects Bulevirtide for Hepatitis D, Compensated Liver Disease. Available online: https:\/\/www.ajmc.com\/view\/fda-rejects-bulevirtide-for-hepatitis-d-compensated-liver-disease."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100097","DOI":"10.1016\/j.hsr.2023.100097","article-title":"Bench-to-Bedside: Translational Development Landscape of Biotechnology in Healthcare","volume":"7","author":"Liao","year":"2023","journal-title":"Health Sci. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e28572","DOI":"10.1002\/jmv.28572","article-title":"MRNA Vaccines: The Future of Prevention of Viral Infections?","volume":"95","author":"Rzymski","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The Clinical Progress of MRNA Vaccines and Immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jmv.27487","article-title":"COVID-19 Vaccinations: The Unknowns, Challenges, and Hopes","volume":"94","author":"Mohamed","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global Impact of the First Year of COVID-19 Vaccination: A Mathematical Modelling Study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","unstructured":"(2023, November 25). COVID-19 Vaccine Doses Administered by Manufacturer. Available online: https:\/\/ourworldindata.org\/grapher\/covid-vaccine-doses-by-manufacturer."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-World Effectiveness of COVID-19 Vaccines: A Literature Review and Meta-Analysis","volume":"114","author":"Zheng","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_41","unstructured":"(2023, September 06). Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05144386."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1128\/JCM.00068-15","article-title":"Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection","volume":"53","author":"Yang","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41598-017-00694-8","article-title":"Evolution of Full-Length Genomes of HBV Quasispecies in Sera of Patients with a Coexistence of HBsAg and Anti-HBs Antibodies","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gencay, M., H\u00fcbner, K., Gohl, P., Seffner, A., Weizenegger, M., Neofytos, D., Batrla, R., Woeste, A., Kim, H.-S., and Westergaard, G. (2017). Ultra-Deep Sequencing Reveals High Prevalence and Broad Structural Diversity of Hepatitis B Surface Antigen Mutations in a Global Population. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172101"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.jhepr.2021.100254","article-title":"Whole Genome Deep Sequencing Analysis of Viral Quasispecies Diversity and Evolution in HBeAg Seroconverters","volume":"3","author":"Lin","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12985-021-01707-9","article-title":"The Dynamic Changes of HBV Quasispecies Diversity in Infancy after Immunoprophylaxis Failure: A Prospective Cohort Study","volume":"18","author":"Li","year":"2021","journal-title":"Virol. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105184","DOI":"10.1016\/j.meegid.2021.105184","article-title":"Analysis of Entire Hepatitis B Virus Genomes Reveals Reversion of Mutations to Wild Type in Natural Infection, a 15 Year Follow-up Study","volume":"97","author":"Chen","year":"2022","journal-title":"Infect. Genet. Evol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Audisio, K., Lia, H., Robinson, N., Rahouma, M., Soletti, G., Cancelli, G., Perezgrovas Olaria, R., Chadow, D., Tam, D., and Vervoort, D. (2022). Impact of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9010019"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1057\/s41599-022-01466-0","article-title":"Impacts of the COVID-19 Pandemic on Scientists\u2019 Productivity in Science, Technology, Engineering, Mathematics (STEM), and Medicine Fields","volume":"9","author":"Heo","year":"2022","journal-title":"Humanit. Soc. Sci. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Pokorska-\u015apiewak, M., Jackowska, T., Kuchar, E., Nitsch-Osuch, A., Paw\u0142owska, M., Babicki, M., Jaroszewicz, J., Szenborn, L., and Wysocki, J. (2023). Key Essentials during the Transition from the Acute Phase of the COVID-19 Pandemic. Vaccines, 11.","DOI":"10.20944\/preprints202308.1245.v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5114\/ceh.2017.67626","article-title":"Recommendations for the Treatment of Hepatitis B in 2017","volume":"2","author":"Flisiak","year":"2017","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_53","first-page":"145","article-title":"Guidelines for the Prevention and Treatment of Chronic Hepatitis B (Version 2022)","volume":"3","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.13635","article-title":"Treatment of Hepatitis B: Is There Still a Role for Interferon?","volume":"38","author":"Grossi","year":"2018","journal-title":"Liver Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 Inhibits HBV Transcription and Replication in Cell Culture and in Humanized Mice by Targeting the Epigenetic Regulation of the Nuclear CccDNA Minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/atm.2017.03.69","article-title":"Alpha-Interferon Treatment in Hepatitis B","volume":"5","author":"Woo","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5009\/gnl.2011.5.3.278","article-title":"Current Nucleos(t)Ide Analogue Therapy for Chronic Hepatitis B","volume":"5","author":"Kim","year":"2011","journal-title":"Gut Liver"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","article-title":"Hepatitis B Surface Antigen (HBsAg) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for HBsAg Loss during Treatment with Nucleoside\/Nucleotide Analogues","volume":"16","author":"Jaroszewicz","year":"2011","journal-title":"Antivir. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.12659\/MSM.903382","article-title":"Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Na\u00efve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels","volume":"23","author":"Shi","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jgh.12476","article-title":"Changes of HBsAg and HBV DNA Levels in Chinese Chronic Hepatitis B Patients after 5 Years of Entecavir Treatment","volume":"29","author":"Seto","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"105348","DOI":"10.1016\/j.antiviral.2022.105348","article-title":"Characterization of the Tenofovir Resistance-Associated Mutations in the Hepatitis B Virus Isolates across Genotypes A to D","volume":"203","author":"Liu","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B Virus Infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","article-title":"Long-Term Continuous Entecavir Therapy in Nucleos(t)Ide-Na\u00efve Chronic Hepatitis B Patients","volume":"57","author":"Ono","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s10620-015-3960-x","article-title":"Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany","volume":"61","author":"Petersen","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","article-title":"Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate plus Peginterferon Alfa-2a: Week 120 Analysis","volume":"63","author":"Ahn","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL Guidance on Stopping Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/liv.14654","article-title":"Long-term Clinical Outcome of HBeAg-negative Chronic Hepatitis B Patients Who Discontinued Nucleos(t)Ide Analogues","volume":"41","author":"Manolakopoulos","year":"2021","journal-title":"Liver Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-Therapy Response after Nucleos(t)Ide Analogue Withdrawal in Patients with Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A Multicenter Randomized-Controlled Trial of Nucleos(t)Ide Analogue Cessation in HBeAg-Negative Chronic Hepatitis B","volume":"78","author":"Stein","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-Term Response after Stopping Tenofovir Disoproxil Fumarate in Non-Cirrhotic HBeAg-Negative Patients\u2014FINITE Study","volume":"67","author":"Berg","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.29497","article-title":"Significance of Definitions of Relapse after Discontinuation of Oral Antivirals in HBeAg-negative Chronic Hepatitis B","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-0042-100286","article-title":"Diagnostischer Wert der quantitativen HBsAg-Bestimmung bei der Hepatitis B-Infektion","volume":"54","author":"Weiskirchen","year":"2016","journal-title":"Z. Gastroenterol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B Core-Related Antigen (HBcrAg) Levels in the Natural History of Hepatitis B Virus Infection in a Large European Cohort Predominantly Infected with Genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Inoue, T., and Tanaka, Y. (2019). The Role of Hepatitis B Core-Related Antigen. Genes, 10.","DOI":"10.3390\/genes10050357"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.02.017","article-title":"Clinical Efficacy of a Novel, High-Sensitivity HBcrAg Assay in the Management of Chronic Hepatitis B and HBV Reactivation","volume":"75","author":"Inoue","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and Hepatitis B Core-related Antigen Predict Outcomes in Hepatitis B e Antigen\u2013Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)Ide Analogue Therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Tu, T., Budzinska, M., Shackel, N., and Urban, S. (2017). HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses, 9.","DOI":"10.3390\/v9040075"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ng.2295","article-title":"Genome-Wide Survey of Recurrent HBV Integration in Hepatocellular Carcinoma","volume":"44","author":"Sung","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-Based Treatment of Chronically Infected Patients and Chimpanzees Reveals That Integrated Hepatitis B Virus DNA Is a Source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3390\/ijms15022892","article-title":"NTCP and beyond: Opening the Door to Unveil Hepatitis B Virus Entry","volume":"15","author":"Watashi","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41426-018-0137-7","article-title":"Bona Fide Receptor for Hepatitis B and D Viral Infections: Mechanism, Research Models and Molecular Drug Targets","volume":"7","author":"Yu","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcmgh.2022.09.012","article-title":"Presence of Intact Hepatitis B Virions in Exosomes","volume":"15","author":"Wu","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1620\/tjem.252.309","article-title":"Exosomes in Hepatitis B Virus Transmission and Related Immune Response","volume":"252","author":"Wang","year":"2020","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13534-021-00199-4","article-title":"Challenges in Delivery Systems for CRISPR-Based Genome Editing and Opportunities of Nanomedicine","volume":"11","author":"Sioson","year":"2021","journal-title":"Biomed. Eng. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic In Vivo Delivery of Gene Editing Agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"ref_88","unstructured":"Costa, J.R., Bejcek, B.E., McGee, J.E., Fogel, A.I., Brimacombe, K.R., and Ketteler, R. (2017). Genome Editing Using Engineered Nucleases and Their Use in Genomic Screening, Eli Lilly & Company and the National Center for Advancing Translational Sciences."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0925-4773(91)90015-X","article-title":"Zinc Finger Proteins: What We Know and What We Would like to Know","volume":"35","author":"Elbaradi","year":"1991","journal-title":"Mech. Dev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-065X.2008.00753.x","article-title":"The Structure, Regulation, and Function of ZAP-70","volume":"228","author":"Deindl","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Huber, R.G., Fan, H., and Bond, P.J. (2015). The Structural Basis for Activation and Inhibition of ZAP-70 Kinase Domain. PLoS Comput. Biol., 11.","DOI":"10.1371\/journal.pcbi.1004560"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.00715-19","article-title":"Characterization of Novel Splice Variants of Zinc Finger Antiviral Protein (ZAP)","volume":"93","author":"Li","year":"2019","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1358\/dof.2012.37.3.1779022","article-title":"Zinc Finger Nucleases: Tailor-Made for Gene Therapy","volume":"37","author":"Chou","year":"2012","journal-title":"Drugs Future"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1534\/genetics.110.117002","article-title":"Targeted Genome Modification in Mice Using Zinc-Finger Nucleases","volume":"186","author":"Carbery","year":"2010","journal-title":"Genetics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583510000089","article-title":"The Discovery of Zinc Fingers and Their Development for Practical Applications in Gene Regulation and Genome Manipulation","volume":"43","author":"Klug","year":"2010","journal-title":"Q. Rev. Biophys."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1534\/genetics.111.131433","article-title":"Genome Engineering with Zinc-Finger Nucleases","volume":"188","author":"Carroll","year":"2011","journal-title":"Genetics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1128\/JVI.00366-08","article-title":"Zinc Finger Proteins Designed to Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue Culture","volume":"82","author":"Zimmerman","year":"2008","journal-title":"J. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Weber, N.D., Stone, D., Sedlak, R.H., De Silva Feelixge, H.S., Roychoudhury, P., Schiffer, J.T., Aubert, M., and Jerome, K.R. (2014). AAV-Mediated Delivery of Zinc Finger Nucleases Targeting Hepatitis B Virus Inhibits Active Replication. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097579"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-Finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12985-015-0245-0","article-title":"The Efficacy of Zinc Finger Antiviral Protein against Hepatitis B Virus Transcription and Replication in Tansgenic Mouse Model","volume":"12","author":"Chen","year":"2015","journal-title":"Virol. J."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Mao, R., Nie, H., Cai, D., Zhang, J., Liu, H., Yan, R., Cuconati, A., Block, T.M., Guo, J.-T., and Guo, H. (2013). Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003494"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: A Widely Applicable Technology for Targeted Genome Editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.ggedit.2021.100007","article-title":"TALE and TALEN Genome Editing Technologies","volume":"2","author":"Becker","year":"2021","journal-title":"Gene Genome Ed."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nmeth.3330","article-title":"Improved Specificity of TALE-Based Genome Editing Using an Expanded RVD Repertoire","volume":"12","author":"Miller","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez Castro, N.G., Bjelic, J., Malhotra, G., Huang, C., and Alsaffar, S.H. (2021). Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910355"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/mt.2013.208","article-title":"TALENs Targeting HBV: Designer Endonuclease Therapies for Viral Infections","volume":"21","author":"Weber","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00439-016-1678-2","article-title":"TALEN Gene Editing Takes Aim on HIV","volume":"135","author":"Benjamin","year":"2016","journal-title":"Hum. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5483\/BMBRep.2016.49.4.260","article-title":"Targeted Disruption of EBNA1 in EBV-Infected Cells Attenuated Cell Growth","volume":"49","author":"Noh","year":"2016","journal-title":"BMB Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41467-020-20672-5","article-title":"TALEN Outperforms Cas9 in Editing Heterochromatin Target Sites","volume":"12","author":"Jain","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-like Effector Nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/mt.2013.212","article-title":"An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-like Effector Nucleases","volume":"22","author":"Chen","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Smith, T., Singh, P., Chmielewski, K.O., Bloom, K., Cathomen, T., Arbuthnot, P., and Ely, A. (2021). Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses, 13.","DOI":"10.3390\/v13071344"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bbrc.2016.08.152","article-title":"Improved Antiviral Efficacy Using TALEN-Mediated Homology Directed Recombination to Introduce Artificial Primary MiRNAs into DNA of Hepatitis B Virus","volume":"478","author":"Dreyer","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Allweiss, L., and Dandri, M. (2017). The Role of CccDNA in HBV Maintenance. Viruses, 9.","DOI":"10.3390\/v9060156"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"36483","DOI":"10.1038\/srep36483","article-title":"Minicircle HBV CccDNA with a Gaussia Luciferase Reporter for Investigating HBV CccDNA Biology and Developing CccDNA-Targeting Drugs","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-Based Methods for Genome Engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 Therapeutics: Progress and Prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_119","unstructured":"Abdelaal, A.S., and Yazdani, S.S. (2020). Genome Engineering via CRISPR-Cas9 System, Elsevier."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Sheridan, C. (2023). The World\u2019s First CRISPR Therapy Is Approved: Who Will Receive It?. Nat. Biotechnol.","DOI":"10.1038\/d41587-023-00016-6"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Akidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O.T., and Hammerschmidt, W. (2021). Highly Efficient CRISPR-Cas9-Mediated Gene Knockout in Primary Human B Cells for Functional Genetic Studies of Epstein-Barr Virus Infection. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009117"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ashraf, M.U., Salman, H.M., Khalid, M.F., Khan, M.H.F., Anwar, S., Afzal, S., Idrees, M., and Chaudhary, S.U. (2021). CRISPR-Cas13a Mediated Targeting of Hepatitis C Virus Internal-Ribosomal Entry Site (IRES) as an Effective Antiviral Strategy. Biomed. Pharmacother., 136.","DOI":"10.1016\/j.biopha.2021.111239"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Hussein, M., Molina, M.A., Berkhout, B., and Herrera-Carrillo, E. (2023). A CRISPR-Cas Cure for HIV\/AIDS. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021563"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virusres.2016.04.003","article-title":"CRISPR\/Cas9 Produces Anti-Hepatitis B Virus Effect in Hepatoma Cells and Transgenic Mouse","volume":"217","author":"Zhu","year":"2016","journal-title":"Virus Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent Inactivation of HBV Genomes by CRISPR\/Cas9-Mediated Non-Cleavage Base Editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Yan, K., Feng, J., Liu, X., Wang, H., Li, Q., Li, J., Xu, T., Sajid, M., Ullah, H., and Zhou, L. (2021). Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR\/SaCas9 Expressed from Liver-Specific Promoters. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.665184"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 Cleavage of Viral DNA Efficiently Suppresses Hepatitis B Virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 Gene Editing of Hepatitis B Virus in Chronically Infected Humanized Mice","volume":"20","author":"Stone","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1128\/JVI.01024-14","article-title":"Recombinant Covalently Closed Circular Hepatitis B Virus DNA Induces Prolonged Viral Persistence in Immunocompetent Mice","volume":"88","author":"Qi","year":"2014","journal-title":"J. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Guo, C., Ma, X., Gao, F., and Guo, Y. (2023). Off-Target Effects in CRISPR\/Cas9 Gene Editing. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1143157"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhepr.2019.09.002","article-title":"Using CRISPR\/Cas9 to Model Human Liver Disease","volume":"1","author":"Furey","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Kallimasioti-Pazi, E.M., Thelakkad Chathoth, K., Taylor, G.C., Meynert, A., Ballinger, T., Kelder, M.J.E., Lalev\u00e9e, S., Sanli, I., Feil, R., and Wood, A.J. (2018). Heterochromatin Delays CRISPR-Cas9 Mutagenesis but Does Not Influence the Outcome of Mutagenic DNA Repair. PLoS Biol., 16.","DOI":"10.1101\/267690"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-1298-9_1","article-title":"RNA Interference: Story and Mechanisms","volume":"Volume 2282","author":"Sioud","year":"2021","journal-title":"Methods in Molecular Biology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients with Hereditary Transthyretin-mediated Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The Current State and Future Directions of RNAi-Based Therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Levanova, A., and Poranen, M.M. (2018). RNA Interference as a Prospective Tool for the Control of Human Viral Infections. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02151"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA Interference Therapy with ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients with Chronic Hepatitis B Infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S0168-8278(17)30843-7","article-title":"A Phase 1 Study to Evaluate Safety and Tolerability of Escalating Single Doses of the Hepatitis B Virus RNA Interference Drug ARC-521 in a Healthy Volunteer Population","volume":"66","author":"Gane","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic SiRNA: State of the Art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_141","unstructured":"Agarwal, K., Gane, E., Cheng, C., Sievert, W., Roberts, S.K., Ahn, S.H., Kim, Y.J., Streinu-Cercel, A., Denning, J., and Symonds, W. (2023, December 04). HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Virally Suppressed Patients with Hepatitis B. Available online: https:\/\/www.natap.org\/2017\/AASLD\/HBcrAg,%20HBV-RNA%20Declines%20in%20A%20Phase%202a%20Study%20Evaluating%20the%20Multi-Dose%20Activity%20of%20ARB-1467%20in%20HBeAg-Positive%20and%20Negative%20Virally%20Suppressed%20Patients%20Wit.pdf."},{"key":"ref_142","unstructured":"(2023, October 25). Bi-Weekly Dosing of ARB-1467 LNP SiRNA in HBeAgNegative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper Declines in HBsAg and Potential Association with IL28b. Available online: https:\/\/www.natap.org\/2017\/AASLD\/AASLD_64.htm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/S0168-8278(17)30831-0","article-title":"Superior Suppression of Hepatitis B Virus DNA and Antigen Levels in a Chimeric Mouse Model When BB-103, a DNA-Directed RNA Interference Agent, Is Coupled with Standard of Care Drugs","volume":"66","author":"Mao","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/acsinfecdis.8b00191","article-title":"ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection","volume":"5","author":"Thi","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_145","unstructured":"Yuen, M.-F., Locarnini, S., Given, B., Schluep, T., Hamilton, J., Biermer, M., Kalmeijer, R., Beumont, M., Lenz, O., and Cloherty, G. (2023, October 25). First Clinical Experience with RNA Interference-Based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)Ide Analogue. Available online: https:\/\/ir.arrowheadpharma.com\/index.php\/static-files\/6d7edbe7-c5a2-46c5-9990-a9cdfec854a9."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.7150\/thno.18114","article-title":"The GRNA-MiRNA-GRNA Ternary Cassette Combining CRISPR\/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-020-80594-6","article-title":"Understanding the Antiviral Effects of RNAi-Based Therapy in HBeAg-Positive Chronic Hepatitis B Infection","volume":"11","author":"Kadelka","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(20)30647-4","article-title":"Preliminary Safety and Antiviral Activity of VIR-2218, an X-Targeting HBV RNAi Therapeutic, in Chronic Hepatitis B Patients","volume":"73","author":"Gane","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(20)30597-3","article-title":"Short-Term Treatment with RNA Interference Therapy, JNJ-3989, Results in Sustained Hepatitis B Surface Antigen Supression in Patients with Chronic Hepatitis B Receiving Nucleos(t)Ide Analogue Treatment","volume":"73","author":"Gane","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_150","unstructured":"Yu, Y., Koenig, A., Livingston, C., van Gijzel, H., Elston, R., Dickens, T., Paff, M.T., Rice, C.M., You, S., and Schneider, W.M. (2023, November 26). Rna Launch System Enables In Vitro Evaluation of Bepirovirsen Efficacy against Hbv Variants. Available online: https:\/\/www.natap.org\/2022\/AASLD\/AASLD_59.htm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.jhep.2022.11.023","article-title":"Reply to: \u201cBepirovirsen\/GSK3389404: Antisense or TLR9 Agonists\u201d?","volume":"78","author":"You","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jhep.2022.09.002","article-title":"Bepirovirsen\/GSK3389404: Antisense or TLR9 Agonists?","volume":"78","author":"Vaillant","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1155\/2014\/549624","article-title":"Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review","volume":"28","author":"Yau","year":"2014","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3748\/wjg.v29.i13.2015","article-title":"Changes in Characteristics of Patients with Hepatitis C Virus-Related Cirrhosis from the Beginning of the Interferon-Free Era","volume":"29","author":"Rzymski","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10555-023-10099-x","article-title":"Oral Delivery of RNAi for Cancer Therapy","volume":"42","author":"Afrin","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug Delivery Systems for RNA Therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1128\/JVI.77.21.11531-11535.2003","article-title":"Human Immunodeficiency Virus Type 1 Escape from RNA Interference","volume":"77","author":"Boden","year":"2003","journal-title":"J. Virol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/JVI.78.5.2601-2605.2004","article-title":"Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition","volume":"78","author":"Das","year":"2004","journal-title":"J. Virol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1128\/JVI.79.2.1027-1035.2005","article-title":"Poliovirus Escape from RNA Interference: Short Interfering RNA-Target Recognition and Implications for Therapeutic Approaches","volume":"79","author":"Gitlin","year":"2005","journal-title":"J. Virol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1128\/JVI.00105-14","article-title":"Inhibition of Hepatitis C Virus in Chimeric Mice by Short Synthetic Hairpin RNAs: Sequence Analysis of Surviving Virus Shows Added Selective Pressure of Combination Therapy","volume":"88","author":"Dallas","year":"2014","journal-title":"J. Virol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3851\/IMP1424","article-title":"Does RNA Interference Provide New Hope for Control of Chronic Hepatitis B Infection?","volume":"14","author":"Wilson","year":"2009","journal-title":"Antivir. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"van den Berg, F., Limani, S.W., Mnyandu, N., Maepa, M.B., Ely, A., and Arbuthnot, P. (2020). Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses, 12.","DOI":"10.3390\/v12080851"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Liu, Y., Maya, S., and Ploss, A. (2021). Animal Models of Hepatitis B Virus Infection\u2013Success, Challenges, and Future Directions. Viruses, 13.","DOI":"10.3390\/v13050777"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA Interference as a Novel Treatment Strategy for Chronic Hepatitis B Infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_165","first-page":"S742","article-title":"ALG-125755, a Small Interfering RNA (SiRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model","volume":"75","author":"Hong","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_166","unstructured":"Taylor, N.P. (2023, December 04). Aligos Culls Another Hepatitis B Asset, Citing Inconclusive Efficacy Data. Available online: https:\/\/www.fiercebiotech.com\/biotech\/aligos-culls-another-hepatitis-b-asset-citing-inconclusive-efficacy-data."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"S1162","DOI":"10.1016\/S0168-8278(23)03303-2","article-title":"Safety, Pharmacokinetics, and Antiviral Activity of Single Ascending Doses of ALG-125755, a GalNAc-Conjugated Small Interfering RNA, in Subjects with Chronic Hepatitis B","volume":"78","author":"Jucov","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_168","unstructured":"Gane, E., Fitzgerald, M., Le, K., Wang, S., Ammar, L., Gupta, K., Schwabe, C., Venkatraman, M., Lin, T.-I., and Fry, J. (2023, December 04). Safety, Tolerability and Pharmacokinetics (PK) of Single Ascending Doses of ALG-125755, a GalNAc-Conjugated Small Interfering RNA (SiRNA), in Healthy Volunteers (HV). Available online: https:\/\/www.aligos.com\/wp-content\/uploads\/2023\/02\/1_ALG-125755_APASL-2023_Clinical-Poster.pdf."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","article-title":"Long-Term Serological, Virological and Histological Responses to RNA Inhibition by ARC-520 in Chinese Chronic Hepatitis B Patients on Entecavir Treatment","volume":"71","author":"Yuen","year":"2022","journal-title":"Gut"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1016\/S0168-8278(17)31850-0","article-title":"A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Virally Suppressed Subjects with Hepatitis B","volume":"66","author":"Gane","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Yuen, M.-F., Heo, J., Nahass, R., Wong, G., Burda, T., Bhamidimarri, K.R., Hu, T.-H., Nguyen, T., Lim, Y.-S., and Chen, C.-Y. (2023, October 23). Preliminary Safety and Antiviral Activity of AB-729 Combination Treatment with Pegylated Interferon Alfa-2a in Virally Suppressed, HBeAg-Negative Subjects with Chronic HBV Infection. Available online: https:\/\/www.arbutusbio.com\/wp-content\/uploads\/2023\/06\/EASL-2023_AB-729-201-IFN-LB-poster_FINAL.pdf.","DOI":"10.1016\/S0168-8278(23)00618-9"},{"key":"ref_172","unstructured":"Thi, E.P., Yuen, M.-F., Gane, E., Sevinsky, H., Sims, K.D., Anderson, M., Lam, A.M., Sofia, M.J., Cloherty, G.A., and Picchio, G. (2023, December 04). Hepatitis B Patients Correlates with Suppression of All HBsAg Isoforms and HBV RNA. Available online: https:\/\/www.postersessiononline.eu\/173580348_eu\/congresos\/ILC2021\/aula\/-PO_2822_ILC2021.pdf."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40268-021-00369-w","article-title":"Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection","volume":"21","author":"Gupta","year":"2021","journal-title":"Drugs R D"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"135965352210938","DOI":"10.1177\/13596535221093856","article-title":"JNJ-73763989 Pharmacokinetics and Safety: Liver-Targeted SiRNAs against Hepatitis B Virus, in Japanese and Non-Japanese Healthy Adults, and Combined with JNJ-56136379 and a Nucleos(t)Ide Analogue in Patients with Chronic Hepatitis B","volume":"27","author":"Gane","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination Treatments Including the Small-Interfering RNA JNJ-3989 Induce Rapid and Sometimes Prolonged Viral Responses in Patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jcph.2214","article-title":"Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants with Moderate Hepatic Impairment","volume":"63","author":"Kakuda","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/acsinfecdis.8b00192","article-title":"Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model","volume":"5","author":"Ye","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5114\/ceh.2017.68831","article-title":"New Directions in Hepatitis B Therapy Research","volume":"3","author":"Lewandowska","year":"2017","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, Tolerability and Antiviral Activity of the Antisense Oligonucleotide Bepirovirsen in Patients with Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","article-title":"Phase IIa, Randomised, Double-Blind Study of GSK3389404 in Patients with Chronic Hepatitis B on Stable Nucleos(t)Ide Therapy","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cpdd.670","article-title":"A Randomized, Double-blind, Placebo-controlled, First-time-in-human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects","volume":"8","author":"Han","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/hep.31920","article-title":"Clinical Study of Single-stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients with Chronic Hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2023.07.026","article-title":"First-in-Human Randomized Study of RNAi Therapeutic RG6346 for Chronic Hepatitis B Virus Infection","volume":"79","author":"Gane","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and Efficacy of REP 2139 and Pegylated Interferon Alfa-2a for Treatment-Naive Patients with Chronic Hepatitis B Virus and Hepatitis D Virus Co-Infection (REP 301 and REP 301-LTF): A Non-Randomised, Open-Label, Phase 2 Trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Na\u00efve to Nucleos(t)Ide Therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus\/Hepatitis Delta Virus Coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jvh.13483","article-title":"Benefit of Transaminase Elevations in Establishing Functional Cure of HBV Infection during Nap-Based Combination Therapy","volume":"28","author":"Bazinet","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/hep4.1767","article-title":"Analysis of HBsAg Immunocomplexes and CccDNA Activity during and Persisting after NAP-Based Therapy","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/hep4.1951","article-title":"HBsAg Isoform Dynamics during NAP-Based Therapy of HBeAg-Negative Chronic HBV and HBV\/HDV Infection","volume":"6","author":"Bazinet","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep43838","article-title":"Nucleic Acid-Based Polymers Effective against Hepatitis B Virus Infection in Patients Don\u2019t Harbor Immunostimulatory Properties in Primary Isolated Liver Cells","volume":"7","author":"Real","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e0205","DOI":"10.1097\/HC9.0000000000000205","article-title":"Rapid Monophasic HBsAg Decline during Nucleic-Acid Polymer\u2013Based Therapy Predicts Functional Cure","volume":"7","author":"Hershkovich","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31855-X","article-title":"Antiviral Activity of GS-5801, a Liver-Targeted Prodrug of a Lysine Demethylase 5 Inhibitor, in a Hepatitis B Virus Primary Human Hepatocyte Infection Model","volume":"66","author":"Gilmore","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.7150\/ijms.26125","article-title":"AGK2, A SIRT2 Inhibitor, Inhibits Hepatitis B Virus Replication In Vitro and In Vivo","volume":"15","author":"Yu","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","article-title":"Dicoumarol, an NQO1 Inhibitor, Blocks CccDNA Transcription by Promoting Degradation of HBx","volume":"74","author":"Cheng","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.3748\/wjg.v27.i23.3182","article-title":"Silencing Hepatitis B Virus Covalently Closed Circular DNA: The Potential of an Epigenetic Therapy Approach","volume":"27","author":"Singh","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_198","first-page":"2169","article-title":"Engineered Zinc-Finger Transcription Factors Inhibit the Replication and Transcription of HBV In Vitro and In Vivo","volume":"41","author":"Luo","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/srep13734","article-title":"CRISPR\/Cas9 Nickase-Mediated Disruption of Hepatitis B Virus Open Reading Frame S and X","volume":"5","author":"Karimova","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Li, H., Sheng, C., Wang, S., Yang, L., Liang, Y., Huang, Y., Liu, H., Li, P., Yang, C., and Yang, X. (2017). Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front. Cell. Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00091"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Rawal, P., Tripathi, D.M., Hemati, H., Kumar, J., Sarin, S.K., Nain, V., and Kaur, S. (2022). Targeted HBx Gene Editing by CRISPR\/Cas9 System Effectively Reduces Epithelial to Mesenchymal Transition and HBV Replication in Hepatoma Cells. Res. Sq.","DOI":"10.21203\/rs.3.rs-1514494\/v1"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2395\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:21Z","timestamp":1760132121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":201,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["v15122395"],"URL":"https:\/\/doi.org\/10.3390\/v15122395","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}